Anthem Bioscienc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
853.35
12.55 (1.49%)
BSENSE

Aug 10

BSE+NSE Vol: 13.49 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ajanta Pharma
Gland Pharma
Emcure Pharma
Ipca Labs
Biocon
Glenmark Pharma
Anthem Bioscienc
Abbott India
Aurobindo Pharma
Alkem Lab
Glaxosmi. Pharma
Why is Anthem Biosciences Ltd ?
1
Low Debt Company with Strong Long Term Fundamental Strength
  • Healthy long term growth as Net Sales has grown by an annual rate of 29.80% and Operating profit at 44.32%
  • Company has a low Debt to Equity ratio (avg) at 0 times
  • The company has been able to generate a Return on Capital Employed (avg) of 31.00% signifying high profitability per unit of total capital (equity and debt)
2
The company declared positive results in Mar'26 after negative results in Dec'25
  • NET SALES(Q) Highest at Rs 610.94 cr
  • PBDIT(Q) Highest at Rs 267.21 cr.
  • OPERATING PROFIT TO NET SALES(Q) Highest at 43.74%
3
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 3.87% over the previous quarter and collectively hold 12.83% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Anthem Bioscienc should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
92.24
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.63
Tax Ratio
26.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.05%
ROCE (avg)
32.62%
ROE (avg)
19.93%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
81
Industry P/E
37
Price to Book Value
15.80
EV to EBIT
71.99
EV to EBITDA
59.50
EV to Capital Employed
21.89
EV to Sales
23.56
PEG Ratio
NA
Dividend Yield
0.23%
ROCE (Latest)
32.47%
ROE (Latest)
20.02%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
PAT(Latest six months)

At Rs 309.03 cr has Grown at 41.49%

-14What is not working for the Company
PAT(Q)

At Rs 119.94 cr has Fallen at -21.2% (vs previous 4Q average

NET SALES(Q)

Lowest at Rs 418.22 cr

PBDIT(Q)

Lowest at Rs 150.57 cr.

PBT LESS OI(Q)

Lowest at Rs 119.69 cr.

Loading Valuation Snapshot...
Here's what is not working for Anthem Bioscienc
Net Sales - Quarterly
At Rs 418.22 cr has Fallen at -21.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 531.08 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 119.69 cr has Fallen at -30.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 173.21 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 119.94 cr has Fallen at -21.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 152.29 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 418.22 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs 150.57 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 119.69 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)